New treatments for kidney cancer by targeting specific proteins
Strategies to Disrupt Oncogenic Transcription in RCC Tumors
This study is looking at how certain proteins in kidney cancer might help it grow, and it’s testing new drugs that could block these proteins to find better treatment options for people with renal cell carcinoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgetown University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-10873183 on NIH RePORTER |
What this research studies
This research focuses on renal cell carcinoma (RCC), a common and deadly form of kidney cancer. The team aims to explore how specific proteins, YAP and TAZ, regulate cancer growth and how inhibiting these proteins can lead to new treatment strategies. By using advanced techniques to analyze tumor samples from patients, the researchers will investigate the effectiveness of new drugs designed to disrupt these proteins' functions. This approach could lead to better therapeutic options for patients suffering from RCC.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with metastatic renal cell carcinoma who have not responded well to existing treatments.
Not a fit: Patients with early-stage renal cell carcinoma or those who do not have a confirmed diagnosis of RCC may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with renal cell carcinoma, potentially improving survival rates.
How similar studies have performed: Previous research has shown promising results in targeting oncogenic pathways in various cancers, suggesting that this approach could be effective for RCC as well.
Where this research is happening
Washington, United States
- Georgetown University — Washington, United States (Active)
Researchers
- Principal investigator: Yi, Chunling — Georgetown University
- Study coordinator: Yi, Chunling
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.